OverviewSuggest Edit
BenevolentAI harnesses artificial intelligence to enhance and accelerate scientific discovery by making sense of highly fragmented information to create new insights and usable knowledge that benefit society. The Company's mission is to bring the power of humans and machines together to make sense of and drive rapid scientific discovery. It's proprietary AI technology, the Judgement Augmented Cognition System uses cutting edge deep learning techniques to change the way knowledge is created, connected and applied, and enables the mass analysis of vast amounts of scientific information.
| Type | Private | |
| Founded | 2013 | |
| HQ | London, GB | Map |
| Website | benevolent.ai | |
| Employee Ratings | More |
Recent NewsAll News
- Baroness Joanna Shield's BenevolentAI Is Reportedly Preparing To Slash Its $2 Billion Valuation
- BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery
- Algorithms vs Alzheimers? BenevolentAI Hits $2B High
- Woodford-backed BenevolentAI raises $115m as founder allays robot fears
Latest Updates
| Employees (est.) (Oct 2019) | 190 | (+4%) |
| Job Openings | 26 |
Key People/Management at BenevolentAI
Kenneth Mulvany
Director
Joanna Shields
Group CEO
Michael Brennan
Head of Corporate Development
Jackie Hunter PhD CBE FBPharmacolS FMedSc
Director
Bart Swanson
Non-Executive Director
Jerome Pesenti
Non-Executive Director
BenevolentAI Office Locations
BenevolentAI has offices in London, Cambridge, Brooklyn and Antwerpen
London, GB (HQ)
4-8 Maple St, Bloomsbury
Cambridge, GB
Minerva Building, Babraham Hall, Babraham
Antwerpen, BE
Franklin Rooseveltplaats 12
Brooklyn, US
81 Prospect St
BenevolentAI Financials and Metrics
Summary Metrics
Founding Date | 2013 |
BenevolentAI total Funding | $305 m |
BenevolentAI latest funding size | $90 m |
Time since last funding | a month ago |
BenevolentAI investors | Temasek Holdings, Lundbeck, Woodford Investment Management, Lansdowne Partners, Upsher Smith Laboratories |
BenevolentAI's latest funding round in September 2019 was reported to be $90 m. In total, BenevolentAI has raised $305 m. BenevolentAI's latest valuation is reported to be $1 b.
BenevolentAI Revenue
Market valuation | 1.0b |
BenevolentAI Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Proximagen |
BenevolentAI Online and Social Media Presence
4.64k Twitter followers
BenevolentAI has 4.64k Twitter Followers. The number of followers has increased 3% month over month and increased 6.2% quarter over quarter
BenevolentAI's Trends
Twitter Engagement Stats for @benevolent_ai
1.7k
Tweets
477
Following
4.6k
Followers
94
Tweets last 30 days
3.3
Avg. likes per Tweet
95.7%
Tweets with engagement
BenevolentAI News and Updates
July 08, 2019
Baroness Joanna Shield's BenevolentAI Is Reportedly Preparing To Slash Its $2 Billion Valuation
The company, led by Baroness Joanna Shields, the former European boss of Facebook, is reportedly raising another round of funding at a valuation "far below" its $2 billion valuation.
May 01, 2019
BenevolentAI starts AI collaboration with AstraZeneca to accelerate drug discovery
BenevolentAI, is an AI company where AI actually means something. Founded in 2013, it focuses on ‘accelerating the journey from data to medicines.’ To achieve that, it’s raised a whopping $202 million to look at early drug discovery to late-stage clinical development and has a research facility in C…
April 19, 2018
Algorithms vs Alzheimers? BenevolentAI Hits $2B High
Some 76 startups now using AI in drug discovery - with traditional discovery then route to market typically taking over a decade
The post Algorithms vs Alzheimers? BenevolentAI Hits $2B High appeared first on Computer Business Review.
April 19, 2018
Woodford-backed BenevolentAI raises $115m as founder allays robot fears
The founder of artificial intelligence (AI) startup BenevolentAI believes robots will be able to exist in a symbiotic relationship with humans, refuting the idea that they will replace all jobs. Speaking to City A.M., Ken Mulvany said AI will "multiply the power of our intellect" in the same way …
April 19, 2018
UPDATE 1-AI drug hunter BenevolentAI worth $2 bln after fund raising
LONDON, April 19 (Reuters) - BenevolentAI, a British drug
developer that uses artificial intelligence to identify new
medicine candidates, said it had raised $115 million in a
funding round that valued it at $2 billion.
April 19, 2018
UK drug discovery startup BenevolentAI raises $115M
U.K.-based artificial intelligence company BenevolentAI Ltd. today announced the completion of a $115 million funding round that values the London startup at a cool $2 billion. The round, said to be one of the largest ever in the AI pharmaceutical sector, was led by BevenolentAI’s existing backers i…
BenevolentAI Blogs
October 15, 2019
Biomedical relation extraction
In a recent paper, we proposed a new relation extraction model built on top
of BERT. Given any paragraph of text (for example, the abstract of a
biomedical journal article), our model will extract all gene-disease pairs
which exhibit a pre-specified relation.
October 07, 2019
Mind the gap: the diversity issue in medical research.
There is a data diversity problem in medical research; spanning from
identifying which topic to study, to selecting patients for clinical
trials. It is critical that researchers collaborate and engage in
collective action to ensure that every patient can benefit from our
innovations and discover…
September 17, 2019
BenevolentAI announces $90 million investment from Temasek
BenevolentAI has raised $90 million from Temasek, a Singapore-headquartered
investment company. The funding will be used to scale and further develop
the Benevolent Platform for drug discovery and development as well as
further progress BenevolentAI drug programmes developed in-house and
through…
September 13, 2019
Advancing Oncology Drug Development with Precision Medicine
Our recent collaboration with Novartis in oncology will help gain a better
understanding of patient and disease heterogeneity by combining expertise
in precision medicine and machine learning to accelerate the process of
delivering the next-generation cancer therapies to the clinic.
September 05, 2019
BenevolentAI announces Agreement with leading healthcare company to leverage BenevolentAI’s technology platform
BenevolentAI have collaborated with Novartis Global Drug Development on an
initial project in oncology, which will see the application of our AI and
machine learning technology to stratify patients and gain a better
understanding of patient and disease heterogeneity to more precisely target
medi…
August 27, 2019
Interpret - Constructing large scale biomedical knowledge bases from scratch with rapid annotation of interpretable patterns
We have developed machine learning methods to improve the way scientists
make sense of huge amounts of data and discover non-obvious relationships
between genes, diseases and molecules, based on existing relationships.
BenevolentAI Frequently Asked Questions
When was BenevolentAI founded?
BenevolentAI was founded in 2013.
Who are BenevolentAI key executives?
BenevolentAI's key executives are Kenneth Mulvany, Joanna Shields and Michael Brennan.
How many employees does BenevolentAI have?
BenevolentAI has 190 employees.
Who are BenevolentAI competitors?
Competitors of BenevolentAI include Lantern Pharma, CloudMedx and Human Longevity.
Where is BenevolentAI headquarters?
BenevolentAI headquarters is located at 4-8 Maple St, Bloomsbury, London.
Where are BenevolentAI offices?
BenevolentAI has offices in London, Cambridge, Brooklyn and Antwerpen.
How many offices does BenevolentAI have?
BenevolentAI has 4 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies